REG - ReNeuron Group plc - Notice of AGM

ReNeuronAnnouncement

24/07/2023 17:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230724:nRSX0132Ha&default-theme=true

RNS Number : 0132H  ReNeuron Group plc  24 July 2023

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Notice of Annual General Meeting

 

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome
technologies, announces that the Notice of Annual General Meeting ("AGM") and
Form of Proxy have today been posted to shareholders and will shortly be
available on the investors section of the Company's website here
(https://www.reneuron.com/investors/general-meeting/) .

 

The AGM will be held at the offices of Covington & Burling LLP, Level 54,
22 Bishopsgate, London EC2N 4BQ on 22 August 2023 at 9.30 a.m.

 

The Board welcomes the opportunity to invite shareholders to attend the AGM in
person. Persons intending to attend and vote at the meeting in person will
need a QR code to access the meeting venue. Such QR code will need to be
displayed on a smartphone or similar device. A QR code will be able to be
obtained in advance by emailing externalproxyqueries@computershare.co.uk with
your full name and email address. Please note that this email address should
be used for this purpose only, and the Registrar will not be able to respond
to any other form of communication or enquiry sent to this email address.
Persons who have not obtained a QR code in advance will be able to obtain one
at the meeting venue.

 

If shareholders are unable to attend the meeting in person, then they are
encouraged to submit their votes by proxy by appointing the Chairman of the
AGM as their proxy, so that their votes can be taken into account.

 

Shareholders are also encouraged to submit any questions for the Chairman to
info@reneuron.com at least 48 hours prior to the Meeting. Shareholders that
are able to attend the AGM in person will also have an opportunity to ask
questions at the Meeting. Where appropriate, questions and answers will be
collated and later published on the Company's website at www.reneuron.com.
(https://www.reneuron.com/)

 

The results of the proposed resolutions will be published on the Company
website and announced via RNS as soon as practicable after the conclusion of
the AGM.

 

 
ENDS

 

 

Enquiries:

 

 ReNeuron                                                              www.reneuron.com/investors (http://www.reneuron.com/investors)
 Iain Ross, Executive Chairman                                         Via Walbrook PR
 John Hawkins, Chief Financial Officer

 Allenby Capital Limited (Nominated Adviser and Broker)                +44 (0)20 3328 5656
 James Reeve/George Payne/Dan Dearden-Williams (Corporate Finance)
 Stefano Aquilino (Sales & Corporate Broking)

 Walbrook PR (Media & Investor Relations)                              +44 (0)20 7933 8780 or reneuron@walbrookpr.com
                                                                       (mailto:reneuron@walbrookpr.com)
 Paul McManus / Alice Woodings      +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About ReNeuron

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug
delivery platform with customisable cellular targeting capabilities for the
delivery of complex drug modalities.

 

Through the generation of several unique and scalable exosome producer cell
lines, our CustomEX™ platform can be optimised for specific tissues targets
and payloads leading to improvements in therapeutic outcome and a reduction in
off-target effects. ReNeuron offers a delivery mechanism for a variety of
payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its
conditionally immortalised induced pluripotent stem cell (iPSC) platform, the
Company can make allogeneic tissue cells of choice and has the potential to
produce exosomes with tissue specific targeting ability.

 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAUSANROKUBUAR